-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $20

Benzinga·05/15/2025 15:50:25
Listen to the news
RBC Capital analyst Brian Abrahams maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price target from $21 to $20.